Nanjing Leads Biolabs Co., Ltd. Class H (9887) AI Stock Analysis

Nanjing Leads Biolabs announced that its Phase II trial of LBL-024 (Opamtistomig), a PD-L1/4-1BB bispecific antibody, as a first-line combination therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma has compl...

Nanjing Leads Biolabs reported that six studies featuring its key oncology assets LBL-024 and LBL-034 have been accepted and published as full abstracts at the 2026 Annual Meeting of the European Society for Medical Oncology. Three of these have been...

Nanjing Leads Biolabs has enrolled the first patient in an open-label, multi-centre Phase Ib/II trial of its self-developed bispecific antibody LBL-024, also known as Opamtistomig, in combination therapy for metastatic colorectal cancer. The study, l...

Nanjing Leads Biolabs said its core drug candidate LBL-024, an anti-PD-L1/4-1BB bispecific antibody, has received Fast Track Designation from the U.S. FDA for first-line treatment of advanced biliary tract cancer. This is the second Fast Track status...

Nanjing Leads Biolabs said its core product LBL-024, a PD-L1/4-1BB bispecific antibody branded as Opamtistomig, has obtained orphan drug designation in Japan for treating extrapulmonary neuroendocrine carcinoma, after previously securing similar stat...

Nanjing Leads Biolabs announced that its pivotal registrational Phase IIb study of LBL-024 (Opamtistomig), a PD-L1/4-1BB bispecific antibody monotherapy for advanced extrapulmonary neuroendocrine carcinoma, has been selected as a Late-Breaking Abstra...

Nanjing Leads Biolabs reported updated Phase II data for its self-developed PD-L1/4–1BB bispecific antibody LBL-024 combined with chemotherapy as a first-line therapy for non-small cell lung cancer, presented at the 2026 World Conference on Lun...

Nanjing Leads Biolabs reported substantial progress across registration, clinical development, platform advancement and commercialization preparations in the first half of 2026, underscoring its ambition to become a global frontrunner in next-generat...

Nanjing Leads Biolabs said its self-developed bispecific antibody LBL-024, branded as Opamtistomig, has moved into the expansion stage of a Phase II trial as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma...

Nanjing Leads Biolabs said China’s National Medical Products Administration has accepted the new drug application for LBL-024, a self-developed PD-L1/4-1BB bispecific antibody, as monotherapy for previously treated advanced extrapulmonary neuro...

Nanjing Leads Biolabs announced that the full abstract of its Phase II clinical study of LBL-024, a PD-L1/4-1BB bispecific antibody, combined with chemotherapy as first-line treatment for non-small cell lung cancer has been published on the World Con...

Nanjing Leads Biolabs has reported that Oblenio Bio, Inc., a U.S. company formed by Aditum Bio, has exercised its option to retain an exclusive worldwide license to develop, manufacture and commercialize LBL-051, a trispecific T-cell engager discover...

Nanjing Leads Biolabs Co., Ltd. has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026. The board will also consider whether to recommend the payment of a dividend, a decisio...

Nanjing Leads Biolabs has reported that its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for first-line treatment of hepatocellular carcinoma has successfully completed the safety run-in assessment and entered...

Nanjing Leads Biolabs announced that its partner Oblenio Bio has dosed the first patients in a Phase Ia, first-in-human clinical trial in Europe of LBL-051, a trispecific T-cell engager targeting BCMA, CD19 and CD3 for refractory autoimmune diseases....

Nanjing Leads Biolabs has received approval from China’s National Medical Products Administration for an Investigational New Drug application for LBL-024, a PD-L1/4-1BB bispecific antibody, in metastatic colorectal cancer. The open-label, multi...

Nanjing Leads Biolabs has completed full patient enrollment in a Phase II clinical study of its PD-L1/4-1BB bispecific antibody LBL-024 (Opamtistomig) as first-line therapy for advanced biliary tract cancer. All 70 patients were enrolled rapidly afte...